One other very cool thing here is that this new treatment represents a whole new family of drugs (very sophisticated at that, per Derek Lowe's assessment). I thought back in the late 2010s with integrase inhibitors (e.g. dolutegravir), there was a real chance they could achieve the 90-95% reduction targets in new cases, and hopefully this new drug makes that even more feasible.
There's always the risk of losing previously effective drugs due to resistance, so the value of redundancy cannot be overstated
There's always the risk of losing previously effective drugs due to resistance, so the value of redundancy cannot be overstated